Canagliflozin Alleviates Progestin Resistance by Suppressing RARβ/CRABP2 Signaling in THRB Knockout Endometrial Cancer Cells

    April 2025 in “ Frontiers in Pharmacology ”
    Ye Yang, Jieyun Zhou, Qiaoying Lv, Qicheng Ni, Baichun Hu, Yulong Wang, Suqing Qu, Guoting Li, Wenjie Yang, Ruihua Zhong, Xiaojun Chen, Yan Zhu
    TLDR Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
    The study investigates the effects of Canagliflozin (CANA) on progestin resistance in THRB knockout endometrial cancer cells. The knockout activated the retinoic acid pathway, contributing to resistance. CANA effectively targeted RARβ and RXRA, downregulated CRABP2, and restored BAX levels, which helped counteract this resistance. The combination of CANA with medroxyprogesterone acetate (MPA) offers a promising new approach to overcoming progestin resistance and improving clinical outcomes in this context.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results